Caribou Biosciences

We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. Our next-generation CRISPR genome-editing technology enables superior specificity and precision. Our patented chRDNA (CRISPR hybrid RNA-DNA) technology drives for complex genome editing, including multiplex gene knockout and insertion, while maintaining genomic integrity. We are developing allogeneic, or off-the-shelf, CAR-T cell therapies to provide broad access and rapid treatment for patients with hematologic malignancies.